Xenoport Inc (NASDAQ:XNPT)

6.27
Delayed Data
As of May 21
 +0.08 / +1.29%
Today’s Change
3.52
Today|||52-Week Range
9.60
-28.51%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$388.6M

Company Description

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company's first product gabapentin enacarbil which is known as Horizant in United States and Regnite in Japan, is developed for the treatment of moderate-to-severe primary restless legs syndrome in adults. The XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. The company's pipeline of products candidates includes potential treatments for patients with Postherpetic Neuralgia, Spasticity and Parkinson's disease. XenoPort was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on May 19, 1999 and is headquartered in Santa Clara, CA.

Contact Information

XenoPort, Inc.
3410 Central Expressway
Santa Clara California 95051
P:(408) 616-7200
Investor Relations:
(408) 616-7220

Employees

Shareholders

Individual stakeholders8.65%
Other institutional49.47%
Mutual fund holders40.93%

Top Executives

Ronald W. BarrettChief Executive Officer & Director
Vincent J. AngottiChief Operating Officer & Executive Vice President
William G. HarrisChief Financial Officer & Senior VP-Finance
Richard K. KimChief Medical Officer & SVP-Clinical Development
Peter A. VirsikSenior Vice President-Corporate Development

To view my watchlist

Not a member yet?

Sign up now for a free account